Cat. No.: DAB-0012324
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human mucolipin-1 protein. Antibodies are purified by peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | MCOLN1 |
| UniProt No. | Q9GZU1 |
| Gene ID | 57192 |
| Gene Description | Mucolipin-1, a member of the transient receptor potential ion channel superfamily, is a lysosomal/late endosome Ca2+ efflux channel that is important in lysosomal biogenesis. Mutations in the mucolipin-1 gene are responsible for the human lysosomal storage disease mucolipidosis type IV, an autosomal recessive neurodegenerative disease. Mucolipin-1 is synthesized as a 580-amino acid protein with six transmembrane domains but can undergo cleavage in the long luminal loop between the first two transmembrane domains. Mucolipin-1 activity has been linked to autophagy and lysosomal biogenesis. Calcium influx through mucolipin-1 activates CaMKKβ and AMPK which activate the autophagy kinase ULK1. Calcium influx is also associated with activation of the calcium-dependent phosphatase calcineurin which can trigger activation of TFEB, a key transcription factor regulating autophagy and lysosomal biogenesis. Mucolipin-1 activity is upregulated by cellular stress, including reactive oxygen species. Phosphorylation of mucolipin-1 by mTOR results in reduced channel activity and autophagic flux. Loss of mucolipin-1 or pharmacological inhibition suppresses autophagy and can reduce tumor growth and metastasis in non-small cell lung cancer and triple-negative breast cancer, suggesting the use of mucolipin-1 antagonists for cancer therapy. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, and 50% glycerol. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
